"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 7 | 7 |
| 2004 | 0 | 9 | 9 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 7 | 7 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 5 | 5 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 5 | 5 |
| 2015 | 3 | 0 | 3 |
| 2016 | 3 | 1 | 4 |
| 2017 | 5 | 3 | 8 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflamm Bowel Dis. 2023 05 02; 29(5):695-704.
-
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2023 01; 57(1):150-151.
-
Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. Dig Dis Sci. 2022 03; 67(3):805-809.
-
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Dig Dis. 2022; 40(5):553-564.
-
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
-
Prevalence of inflammatory bowel disease in patients with pyoderma gangrenosum: A population-based analysis. J Am Acad Dermatol. 2022 06; 86(6):1351-1352.
-
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Na?ve Crohn's Disease. Clin Gastroenterol Hepatol. 2022 07; 20(7):1579-1587.e2.
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
-
The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies. Gut. 2021 11; 70(11):2076-2084.
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.